{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:07:06Z","timestamp":1789232826948,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.mayocp.2026.03.024","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:51:29Z","timestamp":1775544689000},"page":"1380-1391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["How to Manage an Adult Patient With IgA Nephropathy in the Current Era?"],"prefix":"10.1016","volume":"101","author":[{"given":"Ladan","family":"Zand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.mayocp.2026.03.024_bib1","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"issue":"4S","key":"10.1016\/j.mayocp.2026.03.024_bib2","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/ndt\/gfx242","article-title":"Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy","volume":"32","author":"Knoop","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib5","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"10.1016\/j.mayocp.2026.03.024_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233199","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy","volume":"15","author":"Neves","year":"2020","journal-title":"PLoS One"},{"issue":"7-8","key":"10.1016\/j.mayocp.2026.03.024_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000531693","article-title":"Clinicopathological characteristics and impacts on clinical outcomes of thrombotic microangiopathy lesions in patients with immunoglobulin A nephropathy in Thailand","volume":"54","author":"Puapatanakul","year":"2023","journal-title":"Am J Nephrol"},{"issue":"9-10","key":"10.1016\/j.mayocp.2026.03.024_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000533982","article-title":"Clinicopathological features and outcomes of IgA nephropathy with serum antineutrophil cytoplasmic autoantibody positivity","volume":"54","author":"Li","year":"2023","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.024_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2009.09.031","article-title":"Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series","volume":"55","author":"Bantis","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.024_bib12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/ndt\/gfy413","article-title":"Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression","volume":"34","author":"Trimarchi","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.mayocp.2026.03.024_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000526971","article-title":"Collagen IV and podocyte-related gene variants in patients with concurrent IgA nephropathy and thin basement membrane nephropathy","volume":"147","author":"Xu","year":"2023","journal-title":"Nephron"},{"issue":"41","key":"10.1016\/j.mayocp.2026.03.024_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017388","article-title":"Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib15","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.humpath.2014.07.015","article-title":"Defining the spectrum of immunoglobulin A\u2013dominant\/codominant glomerular deposition in diabetic nephropathy","volume":"45","author":"Cossey","year":"2014","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/ndt\/16.6.1183","article-title":"Prospective study on renal outcome of IgA nephropathy superimposed on diabetic glomerulosclerosis in type 2 diabetic patients","volume":"16","author":"Mak","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.024_bib17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2026.03.024_bib18","doi-asserted-by":"crossref","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.mayocp.2026.03.024_bib19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ndt\/gfz267","article-title":"The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy","volume":"36","author":"Bobart","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.024_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ndt\/gfaf197","article-title":"Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index","volume":"41","author":"Vargas-Brochero","year":"2026","journal-title":"Nephrol Dial Transplant"},{"issue":"10417","key":"10.1016\/j.mayocp.2026.03.024_bib21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2026.03.024_bib23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"issue":"10405","key":"10.1016\/j.mayocp.2026.03.024_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.024_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.024_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.024_bib28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2026.03.024_bib30","article-title":"Intensive systolic blood pressure lowering and kidney disease progression in IgA nephropathy: a cohort study","volume":"9","author":"Yu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"23","key":"10.1016\/j.mayocp.2026.03.024_bib31","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11906-022-01181-w","article-title":"Obstructive sleep apnea and hypertension: updates to a critical relationship","volume":"24","author":"Brown","year":"2022","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib34","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1681\/ASN.V12112321","article-title":"Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria","volume":"12","author":"Lehrke","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.024_bib38","first-page":"e114","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"issue":"10335","key":"10.1016\/j.mayocp.2026.03.024_bib39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(22)00461-5","article-title":"Acute glomerulonephritis","volume":"399","author":"Sethi","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.024_bib40","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.03.024_bib41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.024_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2023.10.015","article-title":"Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy","volume":"9","author":"Miao","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.mayocp.2026.03.024_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.03.024_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"issue":"5537","key":"10.1016\/j.mayocp.2026.03.024_bib45","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2026.03.024_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/nep.14367","article-title":"B cell targeting in IgA nephropathy","volume":"29","author":"Suzuki","year":"2024","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.024_bib47","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:52:17Z","timestamp":1785739937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626184511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0025619626184511"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.024","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Manage an Adult Patient With IgA Nephropathy in the Current Era?","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}